Home / Markets / Industries / Industrials
Sunday, March 14, 2010
Eisai To Sell Lymphoma Treatment In Japan This Summer-Nikkei
Dow Jones Newswires
TOKYO -(Dow Jones)- Eisai Co. (4523.TO) plans to begin sales of lymphoma and leukemia treatment Bendamustine in Japan this summer, the Nikkei reports.
Without citing where it obtained the information, the paper said that Eisai hopes to tap strong domestic demand for the treatment.
In 2008, Eisai and SymBio Pharmaceuticals reached a license agreement for the co-development and commercialization of bendamustine hydrochloride in Japan, with exclusive rights retained by SymBio.
-Tokyo Bureau, Dow Jones Newswires; +81-3-6269-2770
Copyright © 2009 Dow Jones Newswires
Fox Business Video
-
-
Health Insurers Raising Premiu...
-
Sep 9, 2010
Gerri's Two Cents: Costs of health-care reform
-
-
-
Fed Handouts on the Rise
-
Sep 9, 2010
1-in-6 Americans receive government handouts
-
-
-
Identifying Credit-Repair Scams
-
Sep 9, 2010
Protecting your credit score
-
-
-
Kelsey Grammer on Right-Wing T...
-
Sep 9, 2010
Grammer on Launch of 'Right Network'
-
-
-
Norfolk Southern CEO on Admini...
-
Sep 9, 2010
Moorman reacts to Treasury Secretary Geithner
-